Exagen (XGN) Competitors

Exagen (NASDAQ:XGN) and Personalis (NASDAQ:PSNL) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, dividends, valuation, risk, institutional ownership and community ranking.

Which has more volatility and risk, XGN or PSNL?

Exagen has a beta of 1.46, meaning that its share price is 46% more volatile than the S&P 500. Comparatively, Personalis has a beta of 1.89, meaning that its share price is 89% more volatile than the S&P 500.

Does the media prefer XGN or PSNL?

In the previous week, Personalis had 1 more articles in the media than Exagen. MarketBeat recorded 5 mentions for Personalis and 4 mentions for Exagen. Exagen's average media sentiment score of 1.06 beat Personalis' score of 0.51 indicating that Exagen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exagen	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Personalis	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Does the MarketBeat Community favor XGN or PSNL?

Personalis received 101 more outperform votes than Exagen when rated by MarketBeat users. Likewise, 68.31% of users gave Personalis an outperform vote while only 58.54% of users gave Exagen an outperform vote.

Company	Underperform	Outperform
Exagen	Outperform Votes 24 58.54%	Underperform Votes 17 41.46%
Personalis	Outperform Votes 125 68.31%	Underperform Votes 58 31.69%

Do institutionals and insiders believe in XGN or PSNL?

75.3% of Exagen shares are owned by institutional investors. Comparatively, 61.9% of Personalis shares are owned by institutional investors. 26.1% of Exagen shares are owned by company insiders. Comparatively, 3.8% of Personalis shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Is XGN or PSNL more profitable?

Exagen has a net margin of -30.36% compared to Personalis' net margin of -104.52%. Personalis' return on equity of -66.07% beat Exagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exagen	-30.36%	-92.58%	-33.74%
Personalis	-104.52%	-66.07%	-41.34%

Do analysts recommend XGN or PSNL?

Exagen currently has a consensus price target of $7.50, suggesting a potential upside of 20.39%. Personalis has a consensus price target of $7.80, suggesting a potential upside of 106.35%. Given Personalis' higher possible upside, analysts plainly believe Personalis is more favorable than Exagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exagen	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Personalis	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has stronger valuation & earnings, XGN or PSNL?

Exagen has higher earnings, but lower revenue than Personalis. Exagen is trading at a lower price-to-earnings ratio than Personalis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exagen	$55.64M	2.00	-$23.69M	-$0.83	-7.51
Personalis	$84.61M	3.95	-$108.30M	-$1.37	-2.76

Summary

Personalis beats Exagen on 10 of the 17 factors compared between the two stocks.